Insilico Medicine(“Insilico”), a global leading generative artificial intelligence (AI)-driven biotechnology company, today announced it has signed a Revolving Loan Facility of up to US$100 million with HSBC, one of the world's largest banks and finan (IMAGE)

InSilico Medicine

Insilico Medicine(“Insilico”), a global leading generative artificial intelligence (AI)-driven biotechnology company, today announced it has signed a Revolving Loan Facility of up to US$100 million with HSBC, one of the world's largest banks and finan

Caption

Insilico is committed to driving advancements in healthcare using cutting-edge AI technology, reducing costs and improving efficiency in early-stage drug development, and meeting unmet clinical needs with higher efficiency and quality. The credit line, provided from HSBC New Economy Fund, will support the expansion of Insilico's proprietary novel drug discovery pipeline and the upgrade of its end-to-end diversified AI platform, Pharma.AI.

Credit

Insilico Medicine & HSBC

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.